Cerus Corporation (CERS) Financial Ratios

Cerus Corporation (CERS) has an ST Score of 66.7 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate CERS a Buy, with a price target of $4.00 (+73.2% vs the current price). Our ST Score grades it B (66.7/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B, Profitability A-, Financial Strength C-, Momentum B+, Growth A+, Forecast A-.

Cerus Corporation (CERS) earns a valuation grade of B, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Cerus Corporation (CERS) earns a growth grade of A+, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Cerus Corporation (CERS) earns a profitability grade of A-, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Cerus Corporation (CERS) earns a financial strength grade of C-, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Cerus Corporation (CERS) is $4.00 from 10 analysts, which is +73.2% versus the recent price of $2.31.

Cerus Corporation (CERS) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.